Neurodegenerative diseases refer to a group of progressive conditions that cause the neurons in the brain and spinal cord to deteriorate over time. These diseases not only cause physical and cognitive impairments but also lead to significant emotional stress and an overall decline in quality of life. Over the last few years, genetics has been pinpointed as an obvious factor in the pathogenesis of these diseases. The discovery of genetic links to neurodegenerative disorders has led to an increased focus on the role of genetic risk factors in disease susceptibility. Genetic mutations, deletions, and alterations have been identified for many neurodegenerative diseases, such as Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease. For instance, the Huntington’s disease-causing CAG repeat mutation is located in the Huntington’s gene. This gene codes for the enzyme Huntingtin, which is found in large concentrations in the brain and implicated in the disease pathogenesis. Parkinson’s disease is linked to several mutations on at least four genes. The most important of these is the LRRK2 gene, which carries a greater risk of developing Parkinson’s compared to other genes. For Alzheimer’s disease, a mutation in the ApoE gene has been found to increase the risk of developing the disease. Furthermore, other genes implicated in the disease's risk include APP, PSEN1, and PSEN2. With the advancements in genetic research and testing, doctors and scientists may be able to develop preventive strategies, appropriate treatments, and even cures for neurodegenerative disorders. The insight gained from genetic studies can help researchers design targeted therapies, unravel pathways involved in the pathogenesis of such diseases, and help patients make informed decisions regarding their health. At the same time, genetic testing for neurodegenerative diseases does come with certain risks, such as having to cope with an unexpected diagnosis, stigma, and anxiety. Thus, genetic testing should only be conducted after taking into consideration the emotional and physical impact it may have on an individual.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom